Urethral cancer: Difference between revisions
→Signs and symptoms: cite penile discharge |
review article |
||
Line 24: | Line 24: | ||
| deaths = |
| deaths = |
||
}} |
}} |
||
'''Urethral cancer''' is [[cancer]] originating from the [[urethra]]. Cancer in this location is rare, and the most common type is papillary [[transitional cell carcinoma]].<ref name="SEER6215ch30">{{cite book|chapter=Chapter 30: Cancers of Rare Sites|pages=251–262|publisher=National Cancer Institute|title=SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics|editor1-last=Ries|editor1-first=LAG|editor2-last=Young|editor2-first=JL|editor3-last=Keel|editor3-first=GE|editor4-last=Eisner|editor4-first=MP|editor5-last=Lin|editor5-first=YD|editor6-last=Horner|editor6-first=M-J|series=SEER Program|volume=NIH Pub. No. 07-6215|place=Bethesda, MD|year=2007|url=http://seer.cancer.gov/publications/survival|url-status=dead|accessdate=18 October 2013|archive-url=https://web.archive.org/web/20131010123756/http://seer.cancer.gov/publications/survival/|archive-date=10 October 2013|df=dmy-all}}</ref> The most common site of urethral cancer is the bulbomembranous urethra. |
'''Urethral cancer''' is a rare [[cancer]] originating from the [[urethra]].<ref name="Janisch2019">{{cite journal |last1=Janisch |first1=Florian |last2=Abufaraj |first2=Mohammad |last3=Fajkovic |first3=Harun |last4=Kimura |first4=Shoji |last5=Iwata |first5=Takehiro |last6=Nyirady |first6=Peter |last7=Rink |first7=Michael |last8=Shariat |first8=Shahrokh F. |title=Current Disease Management of Primary Urethral Carcinoma |journal=European Urology Focus |date=1 September 2019 |volume=5 |issue=5 |pages=722–734 |doi=10.1016/j.euf.2019.07.001 |url=https://www.eu-focus.europeanurology.com/article/S2405-4569(19)30172-5/fulltext |language=English |issn=2405-4569}}</ref> |
||
Cancer in this location is rare, and the most common type is papillary [[transitional cell carcinoma]].<ref name="SEER6215ch30">{{cite book|chapter=Chapter 30: Cancers of Rare Sites|pages=251–262|publisher=National Cancer Institute|title=SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics|editor1-last=Ries|editor1-first=LAG|editor2-last=Young|editor2-first=JL|editor3-last=Keel|editor3-first=GE|editor4-last=Eisner|editor4-first=MP|editor5-last=Lin|editor5-first=YD|editor6-last=Horner|editor6-first=M-J|series=SEER Program|volume=NIH Pub. No. 07-6215|place=Bethesda, MD|year=2007|url=http://seer.cancer.gov/publications/survival|url-status=dead|accessdate=18 October 2013|archive-url=https://web.archive.org/web/20131010123756/http://seer.cancer.gov/publications/survival/|archive-date=10 October 2013|df=dmy-all}}</ref> The most common site of urethral cancer is the bulbomembranous urethra. |
|||
== Signs and symptoms == |
== Signs and symptoms == |
||
Line 43: | Line 45: | ||
== Treatment == |
== Treatment == |
||
Surgery is the most common treatment for cancer of the urethra. One of the following types of surgery may be done: Open excision, Electro-resection with flash, [[Laser surgery]], [[Cystourethrectomy]], [[Cystoprostatectomy]], Anterior body cavity, or Incomplete or basic [[penectomy]] surgery. |
Surgery is the most common treatment for cancer of the urethra.<ref name="Janisch2019"/> One of the following types of surgery may be done: Open excision, Electro-resection with flash, [[Laser surgery]], [[Cystourethrectomy]], [[Cystoprostatectomy]], Anterior body cavity, or Incomplete or basic [[penectomy]] surgery. |
||
Radiation therapy has also been used in some cases.<ref name="Janisch2019"/> |
|||
Radiation therapy has also been used in some cases<ref>{{Cite journal|last=Donovan|first=Amy|last2=Beldham-Collins|first2=Rachael|last3=Turner|first3=Sandra|title=A Case study of the radiation therapy treatment of a transitional cell carcinoma of the distal urethra|url=https://www.onlinelibrary.wiley.com/doi/abs/10.1002/jmrs.371|journal=Journal of Medical Radiation Sciences|language=en|volume=n/a|issue=n/a|doi=10.1002/jmrs.371|issn=2051-3909|doi-access=free}}</ref>. |
|||
[[Chemotherapy]] is sometimes used to destroy urethral cancer cells. It is a systemic urethral cancer treatment (i.e., destroys urethral cancer cells throughout the body) that is administered orally or intravenously. Medications are often used in combination to destroy urethral cancer that has [[Metastasis|metastasized]]. Commonly used drugs include [[cisplatin]], [[vincristine]], and [[methotrexate]]. |
[[Chemotherapy]] is sometimes used to destroy urethral cancer cells. It is a systemic urethral cancer treatment (i.e., destroys urethral cancer cells throughout the body) that is administered orally or intravenously. Medications are often used in combination to destroy urethral cancer that has [[Metastasis|metastasized]]. Commonly used drugs include [[cisplatin]], [[vincristine]], and [[methotrexate]]. |
Revision as of 08:11, 27 December 2020
Urethral cancer | |
---|---|
Micrograph of a urethral cancer, urothelial cell carcinoma, found on a prostate core biopsy. H&E stain. | |
Specialty | Oncology Urology |
Symptoms | Blood in the urine |
Urethral cancer is a rare cancer originating from the urethra.[1]
Cancer in this location is rare, and the most common type is papillary transitional cell carcinoma.[2] The most common site of urethral cancer is the bulbomembranous urethra.
Signs and symptoms
Symptoms that may be caused by urethral cancer include:
- Bloody urethral discharge.[3]
- Blood in the urine.
- Weak or interrupted flow of urine.
- Urination occurs often, painful urination, inability to pass urine.
- A lump or thickness in the perineum or penis.
- Enlarged lymph nodes or pain in the groin or vaginal area.
Risk factors
The main medical risk factors are having bladder cancer or having conditions that cause chronic inflammation in the urethra. People over the age of 60 and white women have the highest risks.
Diagnosis
Diagnosis is established by transurethral biopsy. Types of urethral cancer include transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, and melanoma.
Treatment
Surgery is the most common treatment for cancer of the urethra.[1] One of the following types of surgery may be done: Open excision, Electro-resection with flash, Laser surgery, Cystourethrectomy, Cystoprostatectomy, Anterior body cavity, or Incomplete or basic penectomy surgery.
Radiation therapy has also been used in some cases.[1]
Chemotherapy is sometimes used to destroy urethral cancer cells. It is a systemic urethral cancer treatment (i.e., destroys urethral cancer cells throughout the body) that is administered orally or intravenously. Medications are often used in combination to destroy urethral cancer that has metastasized. Commonly used drugs include cisplatin, vincristine, and methotrexate.
Side effects include anemia (causing fatigue, weakness), nausea and vomiting, loss of appetite, hair loss, mouth sores, increased risk for infection, shortness of breath, or excessive bleeding and bruising.[4]
See also
References
This article needs additional citations for verification. (March 2009) |
- ^ a b c Janisch, Florian; Abufaraj, Mohammad; Fajkovic, Harun; Kimura, Shoji; Iwata, Takehiro; Nyirady, Peter; Rink, Michael; Shariat, Shahrokh F. (1 September 2019). "Current Disease Management of Primary Urethral Carcinoma". European Urology Focus. 5 (5): 722–734. doi:10.1016/j.euf.2019.07.001. ISSN 2405-4569.
- ^ Ries, LAG; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J, eds. (2007). "Chapter 30: Cancers of Rare Sites". SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics. SEER Program. Vol. NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute. pp. 251–262. Archived from the original on 10 October 2013. Retrieved 18 October 2013.
- ^ Kahan, Scott; Miller, Redonda; Smith, Ellen G. (2008). "126. Penile Discharge". Signs and Symptoms. Lippincott Williams & Wilkins. ISBN 978-0-7817-7043-9.
- ^ Urethral Cancer Treatment